Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug can restore social ability in schizophrenics

06.12.2007
The social behaviour of rats displaying schizophrenic tendencies is restored when they are treated with two new potential drugs that seem to have unique effects on dopaminergic signalling. This is a conclusion of a thesis from the Sahlgrenska Academy at Göteborg University in Sweden.

Schizophrenia is a severe psychiatric disorder with symptoms that include hallucinations and delusions. Other common effects are social withdrawal, lack of initiative, dulled emotions, and difficulty in experiencing pleasure.

"The treatment available for schizophrenic patients hardly ever relieves impairment of social function. If patients are to have satisfactory lives, we must find new drugs," says pharmacologist Johan Rung, who has studied the two drug candidates, OSU6162 and ACR16.

In the studies, rats were given a type of drug known for inducing a schizophrenia-like state in humans, and this reduced the rats' social behaviour. When the rats were given the two drug candidates, normal social behaviour was restored.

"This indicates that the two drugs can relieve the schizophrenic's lack of ability to interact socially, and also have positive effects on a number of other symptoms thought to be caused by the same underlying mechanisms," says Johan Rung.

In contrast to other drugs that only reduce dopaminergic signalling in the brain, the two new substances seem to be able to both reduce and strengthen the signalling, depending on the circumstances.

"This is a property that can be particularly beneficial in the treatment of schizophrenia. Different groups of symptoms can be linked to either elevated or reduced dopaminergic signalling in different parts of the brain," says Johan Rung.

More years of research lie ahead before doctors can prescribe the new substances as drugs for their patients. An international drug company has recently started to test ACR16 on patients. The other substance, OSU6162, has also been tested on a small number of schizophrenia patients, and the results are promising.

SCHIZOPHRENIA
Schizophrenia is a psychiatric disease that afflicts one percent of the population. There is no cure, but psychotic symptoms can be treated with psychopharmaceuticals. The onset usually occurs when people are in their twenties. The condition is often severe, and most patients never return to school or work.
For more information, please contact:
Johan Rung, pharmacologist, telephone: +46 (0)31-786 33 28, +46 (0)70-350 30 58, e-mail: johan.rung@psychiat.gu.se
Supervisor:
Associate Professor Maria Carlsson, telephone: +46 (0)31-786 33 28, e-mail: maria.carlsson@psychiat.gu.se
Doctor of Philosophy (Medicine) thesis at the Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation.

Title of thesis: Dopaminergic stabilizers for the treatment of schizophrenia; rat studies focusing on negative symptoms and mechanisms of action

Elin Lindström Claessen
Information Officer, Sahlgrenska Academy at Göteborg University
Telephone: +46 (0)31-786 3837, +46 (0)70-829 43 03
e-mail: elin.lindstrom@sahlgrenska.gu.se
The Sahlgrenska Academy is the faculty of health sciences at Göteborg University. Education and research are conducted within the fields of medicine, odontology and health care sciences. About 4,000 undergraduate students and 1,000 postgraduate students are enrolled at the Sahlgrenska Academy. The Academy has 1,500 employees, 850 of which are researchers and/or teachers.

Elin Lindström Classeb | idw
Further information:
http://www.vr.se

Further reports about: Academy Rung Sahlgrenska patients schizophrenic signalling symptoms

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>